Journal of Hepatology

Papers
(The H4-Index of Journal of Hepatology is 106. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
JHEP at a glance (October 2024)2995
Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis1785
Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver1596
Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW0141313
The anti-fibrotic efficacy of Adelmidrol depends in the level of hepatic PPAR gama1245
The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency1181
Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis1106
Gut-liver crosstalk in hepatocellular carcinoma and non-selective beta-blockers: is there a link?640
Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy412
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B391
Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece358
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis344
Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis294
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease291
Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients290
Eliminating viral hepatitis one island at a time-the Hainan experience286
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)271
Assessing progress towards achieving regional hepatitis B control goal-nationwide serosurvey among children, Uzbekistan, 2022258
PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes253
The health economic outcomes of trial ACTG5360/MINMON248
The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure247
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction244
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease240
An explainable artificial intelligence model for prediction of high-risk non-alcoholic steatohepatitis235
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers234
Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona229
Automation of hepatitis C screening through electronic health record algorithm229
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021227
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis213
Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making209
A new nuclear-erythroid-2-related factor 2 activator for the treatment of non-alcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices205
Effect of housing temperature on non-alcoholic fatty liver disease development in C57BL/6N mice203
Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan195
Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD195
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm192
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study191
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis190
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study187
Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling184
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis184
Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease183
The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus178
Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands176
Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis175
Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease175
Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)173
CyberLiver Animal Recognition Test (CL-ART): a novel remote monitoring tool to assess minimal hepatic encephalopathy170
Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test169
Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis167
Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)166
Endoscopic glue injection v/s endoscopic human thrombin injection for bleeding gastric varics -a randomized controlled trial162
Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years’ experience in a tertiary referral center with genotyping facility159
Neutrophil gelatinase-associated lipocalin predicts response to terlipressin and albumin in patients with hepatorenal syndrome158
Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study156
Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions153
miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC152
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis151
TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD147
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)146
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis144
Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study144
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease139
Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B138
Reply to: Correspondence on “EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update”137
MetALD accounts for a large part of what we call MASLD!136
THU-192 Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis136
WED-279 No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/ Emtricitabine/Tenofovir Alafenamide134
WED-367-YI Frequency and risk factors of fibrosis staging discrepancies between transient elastography and liver biopsy in patients with metabolic-associated steatotic liver disease: role of obesity a132
WED-373 Agreement between hepatic histology and non-invasive methods and their ability to detect MASLD/MASH among morbidly obese patients undergoing bariatric surgery: an egyptian crosssectional study131
SAT-417-YI Sex disparities in response to low-carb, high-fat diet in MASLD131
SAT-436 Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study127
WED-511 FIB-4 for identifying chronic liver disease patients requiring HCC surveillance126
FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD125
WED-405 PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness124
TOP-016 Genetic determinants of hepatitis B surface antibody disappearance in Taiwan’s vaccinated generations: a genome- wide association study123
WED-490 Ultrasound-derived visceral adipose tissue: an easily obtainable adiposity index strongly associated with metabolic dysfunctionassociated steatotic liver disease and metabolic parameters123
FRI-010 Economic evaluation of biomarker-base surveillance for hepatocellular carcinoma in thai patients with compensated liver cirrhosis123
FRI-335 Therapeutic potential of a GHRH analog in experimental MASLD123
TOP-505 Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States122
THU-405 Impact of ultra processed foods on metabolic dysfunctionassociated steatotic liver disease: limitations of the NOVA classification122
FRI-024 Living with liver disease: patient and carer experiences in the United Kingdom121
THU-069 A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C120
SAT-162 Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition120
TOP-072-YI Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance119
FRI-044 Dynamic adaptations of CD8+γδ T cells in acute and chronic hepatitis E virus infection119
WED-184 Assessment of impact of ascitic fluid polymorphonuclear count on development of spontaneous bacterial peritonitis and survival in patients with liver cirrhosis and ascites119
WED-164 Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results117
FRI-036 Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure117
SAT-205 Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma116
TOP-508 Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus116
FRI-481 Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma115
SAT-178 Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study115
FRI-062 Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure115
THU-334 Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study115
THU-133-YI Risk of hypoglycemia in people with cirrhosis without diabetes115
WED-121 Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection114
FRI-328 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes113
THU-308-YI Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis111
SAT-136-YI Identification of prognosis determining risk factors in outpatients with cirrhosis111
THU-178 Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis110
FRI-258 No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes109
WED-145 Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study109
FRI-260 Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy108
OS-020 Reviewing the utility of genetic cholestasis testing in adults with cholestatic liver disease107
THU-270 HBV genotype association with response to xalnesiran in nucleos (t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study107
LBP-003 DR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hyp106
GS-012 Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, doubleblind, placebo-controlled, phase 2b trial (SYMMETRY)106
0.25905203819275